FTC clears Valeant Pharma's purchase of Medicis
NEW YORK (AP) — Canadian drugmaker Valeant Pharmaceuticals International Inc. said Friday that the Federal Trade Commission cleared its proposed purchase of dermatology products maker Medicis Pharmaceutical Corp.
Valeant said the antitrust regulatory agency has terminated a mandatory review of the deal. Valeant, which is based in Montreal, agreed to buy Medicis in September for $44 per share, or about $2.6 billion. That represented a premium of 39 percent over the latest closing price of Medicis stock.
Medicis shareholders are scheduled to vote on the deal on Dec. 7. The companies hope to complete the sale in early 2013.
Shares of Valeant rose $1.37, or 2.6 percent, to $53.69 in morning trading. Medicis stock picked up 50 cents to $43.29.
Business Photo Galleriesview all
- 14605Oklahoma tornadoes: The 'Big Dog,' the little boy and the hug that triumphs over tragedy
- 9594Finding Addyson – One family's struggle in the Moore tornado
- 8537Oklahoma tornadoes: Cost, custom keep basements scarce
- 8009Oklahoma tornadoes: Plaza Towers Elementary School teacher shoved students into bathroom as wall collapsed
- 6980Oklahoma tornadoes: Woman meets the military officer who shared the clothes off his back
- 6486Miranda Lambert, Reba McEntire, Vince Gill to join Blake Shelton at "Healing in the Heartland" Oklahoma tornado benefit
- 6299Story behind the photo: Family members describe desperate search for one another after EF5 twister